𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms

✍ Scribed by Okada, Satoshi ;Kamb, Mary L. ;Pandey, Janardan P. ;Philen, Rossanne M. ;Love, Lori A. ;Miller, Frederick W.

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
81 KB
Volume
61
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To assess L‐tryptophan (LT) dose, age, sex, and immunogenetic markers as possible risk or protective factors for the development of LT‐associated eosinophilia–myalgia syndrome (EMS) and related clinical findings.

Methods

HLA–DRB1 and DQA1 allele typing and Gm/Km phenotyping were performed on a cohort of 94 white subjects with documented LT ingestion and standardized evaluations. Multivariate analyses compared LT dose, age, sex, and alleles among groups of subjects who ingested LT and subsequently developed surveillance criteria for EMS, developed EMS or characteristic features of EMS (EMS spectrum disorder), or developed no features of EMS (unaffected).

Results

Considering all sources of LT, higher LT dose (odds ratio [OR] 1.4, 95% confidence interval [95% CI] 1.1–1.8), age >45 years (OR 3.0, 95% CI 1.0–8.8), and HLA–DRB1*03 (OR 3.9, 95% CI 1.2–15.2), DRB1*04 (OR 3.9, 95% CI 1.1–16.4), and DQA1*0601 (OR 13.7, 95% CI 1.3–1.8) were risk factors for the development of EMS, whereas DRB1*07 (OR 0.12, 95% CI 0.02–0.48) and DQA1*0501 (OR 0.23, 95% CI 0.05–0.85) were protective. Similar risk and protective factors were seen for developing EMS following ingestion of implicated LT, except that DRB1*03 was not a risk factor and DQA1*0201 was an additional protective factor. EMS spectrum disorder also showed similar findings, but with DRB1*04 being a risk factor and DRB1*07 and DQA1*0201 being protective. There were no differences in sex distribution, Gm/Km allotypes, or Gm/Km phenotypes among any groups.

Conclusion

In addition to the xenobiotic dose and subject age, polymorphisms in immune response genes may underlie the development of certain xenobiotic‐induced immune‐mediated disorders, and these findings may have implications for future related epidemics.

📜 SIMILAR VOLUMES

The eosinophilia-myalgia syndrome associ
The eosinophilia-myalgia syndrome associated with ingestion of l-tryptophan
✍ Lawrence E. Shulman 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB

physicians in New Mexico notified the New Mexico Department of Health and Environment of 3 patients with marked eosinophilia and severe. incapacitating myalgia who had been taking the amino acid L-tryptophan (orally) and whose illness, after thorough clinical evaluation, seemed both unusual and obsc

L-tryptophan—associated eosinophilic fas
L-tryptophan—associated eosinophilic fasciitis prior to the 1989 eosinophilia—Myalgia syndrome outbreak
✍ Jonathan R. Hibbs; Barbara Mittleman; Paula Hill; Thomas A. Medsger Jr. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

Objective. To investigate the relationship between L-tryptophan (LT) ingestion and eosinophilic fasciitis (EF) occurring prior to the outbreak of eosinophiliamyalgia syndrome in 1989. ## Methods. Interviews and record reviews of 45 EF case-patients and 126 polymyositis patients (controls) diagnosed

Absent neutrophil alkaline phosphatase i
Absent neutrophil alkaline phosphatase in the eosinophilia myalgia syndrome associated with L-tryptophan use
✍ Dr. Jeffrry P. Jaffe; Elie Gertner; Wesley Miller 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB

The clinical constellation of leukocytosis, thrombocytosis, and low or absent stainable neutrophil alkaline phosphatase (NAP) is considered characteristic of chronic myelogenous leukemia (CML) [l]. CML with eosinophilic differentiation (eosinophilic leukemia) is well described [2], and leukemia and

Rapid HPLC screening method for contamin
Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome
✍ Brian L. Williamson; Andy J. Tomlinson; Kyle M. Hurth; Manuel Posada de la Paz; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

In 1981 a massive food-borne epidemic, termed the toxic oil syndrome (TOS), occurred in Spain. Eight years later a closely related disease, the eosinophilia myalgia syndrome (EMS), was reported in the USA with many additional cases being reported worldwide. Although EMS was linked to the ingestion o